Brief: Lilly's Zepbound (Tirzepatide 10 Mg And 15 Mg) Was Associated With More Weight Loss Than Wegovy Hd (Semaglutide Injection 7.2 Mg) In A New Indirect Treatment Comparison
29/09/2026 12:04
BRIEF-Lilly's Zepbound (Tirzepatide 10 Mg And 15 Mg) Was Associated With More Weight Loss Than Wegovy Hd (Semaglutide Injection 7.2 Mg) In A New Indirect Treatment Comparison Sept 29 (Reuters) - Eli Lilly and Company LLY.N:
LILLY'S ZEPBOUND (TIRZEPATIDE 10 MG AND 15 MG) WAS ASSOCIATED WITH MORE WEIGHT LOSS THAN WEGOVY HD (SEMAGLUTIDE INJECTION 7.2 MG) IN A NEW INDIRECT TREATMENT COMPARISON
ELI LILLY - ZEPBOUND 15 MG SHOWS 4.5% GREATER WEIGHT LOSS THAN WEGOVY HD IN ADULTS WITH OBESITY
ELI LILLY - ZEPBOUND 10 MG AND 15 MG SHOW COMPARABLE ADVERSE EVENT DISCONTINUATION RATES TO WEGOVY HD
ELI LILLY - ZEPBOUND ACHIEVES 20.2% WEIGHT REDUCTION VERSUS 13.7% FOR WEGOVY AT 72 WEEKS
ELI LILLY - ZEPBOUND 15 MG USERS HAVE OVER THREE TIMES THE ODDS OF 20% WEIGHT REDUCTION VERSUS WEGOVY HD
Source text: ID:nPn15dtHya
Further company coverage: LLY.N
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Eli Lilly and
See all newsUS stocks weekly: Spooky
Street View: Next-generation drugs bolster Lilly's growth outlook
US STOCKS-Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
US STOCKS-Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
US STOCKS-Wall Street slides as Alphabet revenue miss revives AI capex jitters